Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.34 |
| ▸ | CNR1 | P21554 | 4/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6568848 | 0.89 | RARB (0.36) | RARARARBRARGGLATSHR | |
| SCHEMBL7944733 | 0.84 | TNKS2 (0.37) | CNR2RARARARBRARGGLA | |
| SCHEMBL6568767 | 0.84 | GLA (0.44) | CNR2CNR1ALOX5RARBRARG | |
| SCHEMBL6567296 | 0.81 | GLA (0.35) | RARARARBRARGGLATSHR | |
| SCHEMBL7940198 | 0.78 | RARA (0.33) | RARARARBRARGGLATSHR | |
| SCHEMBL7944933 | 0.76 | TNKS2 (0.38) | CNR2RARARARBRARGGLA | |
| SCHEMBL7796429 | 0.76 | CYP26B1 (0.41) | RARARARBRARG | |
| SCHEMBL7941069 | 0.75 | ALDH1A1 (0.37) | ALOX5RARARARBRARG | |
| SCHEMBL3808966 | 0.74 | GLA (0.47) | RARARARBRARGGLATSHR | |
| SCHEMBL6567008 | 0.73 | TNKS2 (0.36) | RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1484334-A2 | Process for producing phosphite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20040225145-A1 | Process for producing phosphite | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-11-11 | — | — | US | disclosed |
| EP-0823435-B1 | Phosphites, process for producing the same and their use | SUMITOMO CHEMICAL CO (JP) | 2001-11-21 | — | — | EP | disclosed |
| US-5889095-A | OXYGEN AND HEAT RESISTANCE | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 1999-03-30 | — | — | US | disclosed |
| EP-0823435-A2 | Phosphites, process for producing the same and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225145-A1 | Process for producing phosphite | PHOSPHO1, PLCG1, PLCG2 | CNR2 1787/4885CNR1 1365/4885ALOX5 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.